Use of Fragmin^® for the prevention of clotting in the extracorporeal circulation during haemodialysis

Reduce the risk of venous thromboembolism (VTE) in patients undergoing dialysis¹

Indication:

Prevention of clotting in the extracorporeal circulation during haemodialysis or haemofiltration, in patients with chronic renal insufficiency or acute renal failure¹

Dosage for haemodialysis/haemofiltration¹**

^** Fragmin^® does NOT routinely require dose adjustment but caution should be exercised in patients where there is an increased risk of bleeding complications, e.g. in severe renal failure. Monitoring of anti-Xa levels should be considered in patients with renal failure.

Reference

1. Fragmin SmPC [Haemodialysis/Haemofiltration (10,000 IU/1 ml & 10,000 IU/4 ml ampoules)]. Available at: https://www.medicines.org.uk/emc/product/4251 and https://www.medicines.org.uk/emc/product/4244

*Including, but not limited to: congestive cardiac failure (NYHA class III or IV), acute respiratory failure or acute infection, who also have a predisposing risk factor for VTE such as age over 75 years, obesity, cancer or previous history of VTE.~
†In patients with chronic renal insufficiency or acute renal failure.